Drugs / BMS-184476
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003705 | Nov 1997 → ? | cancer of unknown primary site | San Antonio Cancer Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-184476 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003705 ↗ |
| Known as | 7-((methylthio)methyl)paclitaxel | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297267 ↗ |
| Modality | Small molecule | “Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.” PMID 11331328 ↗ May 2001 |
| Route | Intravenous | “PURPOSE: To assess the feasibility, toxicity, pharmacokinetics, and preliminary activity of BMS-184476 administered as a 1-hour intravenous (IV) infusion every 3 weeks.” PMID 11331328 ↗ May 2001 |